Marcaine Rachianesthesie may be available in the countries listed below.
Bupivacaine is reported as an ingredient of Marcaine Rachianesthesie in the following countries:
International Drug Name Search
Rhine may be available in the countries listed below.
Ranitidine is reported as an ingredient of Rhine in the following countries:
International Drug Name Search
Iquinol may be available in the countries listed below.
Ofloxacin is reported as an ingredient of Iquinol in the following countries:
International Drug Name Search
Apo-Seleg may be available in the countries listed below.
Selegiline hydrochloride (a derivative of Selegiline) is reported as an ingredient of Apo-Seleg in the following countries:
International Drug Name Search
In the US, Antidotum Thallii-Heyl is a member of the drug class antidotes.
Prussian Blue is reported as an ingredient of Antidotum Thallii-Heyl in the following countries:
International Drug Name Search
Ceflacid may be available in the countries listed below.
Cefaclor monohydrate (a derivative of Cefaclor) is reported as an ingredient of Ceflacid in the following countries:
International Drug Name Search
Klonalcrom may be available in the countries listed below.
Cromoglicic Acid disodium salt (a derivative of Cromoglicic Acid) is reported as an ingredient of Klonalcrom in the following countries:
International Drug Name Search
Proquin may be available in the countries listed below.
Ciprofloxacin hydrochloride (a derivative of Ciprofloxacin) is reported as an ingredient of Proquin in the following countries:
International Drug Name Search
Magnecyl may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Acetylsalicylic Acid is reported as an ingredient of Magnecyl in the following countries:
International Drug Name Search
Akineton SR may be available in the countries listed below.
Biperiden hydrochloride (a derivative of Biperiden) is reported as an ingredient of Akineton SR in the following countries:
International Drug Name Search
Procion may be available in the countries listed below.
Prednisone is reported as an ingredient of Procion in the following countries:
International Drug Name Search
KOGENATE Bayer 2000 IU powder and solvent for solution for injection.
2.1 General description
Each vial contains nominally 2000 IU human coagulation factor VIII (octocog alfa).
Human coagulation factor VIII is produced by recombinant DNA technology (rDNA) in baby hamster kidney cells containing the human factor VIII gene.
2.2 Qualitative and quantitative composition
One ml of KOGENATE Bayer 2000 IU contains approximately 400 IU (2000 IU / 5.0 ml) of human coagulation factor VIII (octocog alfa) after reconstitution.
The potency (IU) is determined using the one-stage clotting assay against the FDA Mega standard which was calibrated against WHO standard in International Units (IU).
The specific activity of KOGENATE Bayer is approximately 4000 IU/mg protein.
Solvent: water for injections.
For a full list of excipients, see section 6.1.
Powder and solvent for solution for injection.
Powder: dry white to slightly yellow powder or cake.
Solvent: water for injection, a clear, colourless solution.
The reconstituted medicinal product is a clear and colourless solution.
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
This preparation does not contain von Willebrand factor and is therefore not indicated in von Willebrand's disease.
Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia.
Posology
The number of units of factor VIII administered is expressed in International Units (IU), which are related to the current WHO standard for factor VIII products. Factor VIII activity in plasma is expressed either as a percentage (relative to normal human plasma) or in International Units (relative to the International Standard for factor VIII in plasma). One International Unit (IU) of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma. The calculation of the required dose of factor VIII is based on the empirical finding that 1 International Unit (IU) factor VIII per kg body weight raises the plasma factor VIII activity by 1.5% to 2.5% of normal activity. The required dose is determined using the following formulae:
| |
|
|
On demand treatment
The dose, frequency and duration of the substitution therapy must be individualised according to the patient's needs (weight, severity of disorder of the haemostatic function, the site and extent of the bleeding, the presence of inhibitors, and the factor VIII level desired).
The following table provides a guide for factor VIII minimum blood levels. In the case of the haemorrhagic events listed, the factor VIII activity should not fall below the given level (in % of normal) in the corresponding period:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The amount to be administered and the frequency of administration should always be adapted according to the clinical effectiveness in the individual case. Under certain circumstances larger amounts than those calculated may be required, especially in the case of the initial dose.
During the course of treatment, appropriate determination of factor VIII levels is advised in order to guide the dose to be administered and the frequency at which to repeat the infusions. In the case of major surgical interventions in particular, precise monitoring of the substitution therapy by means of coagulation analysis (plasma factor VIII activity) is indispensable. Individual patients may vary in their response to factor VIII, achieving different levels of in vivo recovery and demonstrating different half-lives.
Continuous Infusion
It has been shown in a clinical study performed with adult haemophilia A patients who undergo a major surgery that KOGENATE Bayer can be used for continuous infusion in surgeries (pre-, during and postoperative). In this study heparin was used to prevent thrombophlebitis at the infusion site as with any other long term intravenous infusions. For the calculation of the initial infusion rate, clearance can be obtained by performing a pre-surgery decay curve, or by starting from an average population value (3.0-3.5 ml/h/kg) and then adjust accordingly.
Infusion rate (in IU/kg/h) = Clearance (in ml/h/kg) × desired factor VIII level (in IU/ml)
For continuous infusion, clinical and in vitro stability has been demonstrated using ambulatory pumps with a PVC reservoir. KOGENATE Bayer contains low level of polysorbate-80 as an excipient, which is known to increase the rate of di-(2-ethylhexyl)phthalate (DEHP) extraction from polyvinyl chloride (PVC) materials. This should be considered for a continuous infusion administration.
Prophylaxis
For long term prophylaxis against bleeding in patients with severe haemophilia A, the usual doses are 20 to 40 IU of KOGENATE Bayer per kg body weight at intervals of 2 to 3 days.
In some cases, especially in younger patients, shorter dose intervals or higher doses may be necessary.
Paediatric population
Data have been obtained from clinical studies in 61 children under 6 years of age and non-interventional studies in children of all ages.
Patients with inhibitors
Patients should be monitored for the development of factor VIII inhibitors. If the expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, an assay should be performed to determine if a factor VIII inhibitor is present. If the inhibitor is present at levels less than 10 Bethesda Units (BU) per ml, administration of additional recombinant coagulation factor VIII may neutralise the inhibitor and permit continued clinically effective therapy with KOGENATE Bayer. However, in the presence of an inhibitor the doses required are variable and must be adjusted according to clinical response and monitoring of plasma factor VIII activity. In patients with inhibitor titres above 10 BU or with high anamnestic response, the use of (activated) prothrombin complex concentrate (PCC) or recombinant activated factor VII (rFVIIa) preparations has to be considered. These therapies should be directed by physicians with experience in the care of patients with haemophilia.
Method of administration
For intravenous use.
KOGENATE Bayer should be injected intravenously over several minutes. The rate of administration should be determined by the patient's comfort level (maximal rate of infusion: 2 ml/min).
Continuous infusion
KOGENATE Bayer can be infused by continuous infusion. The infusion rate should be calculated based on the clearance and the desired FVIII level.
Example: for a 75 kg patient with a clearance of 3 ml/h/kg, the initial infusion rate would be 3 IU/h/kg to achieve a FVIII level of 100%. For calculation of ml/hour, multiply infusion rate in IU/h/kg by kg bw/concentration of solution (IU/ml).
Example for calculation of infusion rate for continuous infusion after initial bolus injection
|
|
| |||
|
| ||||
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
|
Higher infusion rates may be required in conditions with accelerated clearance during major bleedings or extensive tissue damage during surgical interventions.
After the initial 24 hours of continuous infusion, the clearance should be recalculated every day using the steady state equation with the measured FVIII level and the rate of infusion using the following equation:
clearance = infusion rate/actual FVIII level.
During continuous infusion, infusion bags should be changed every 24 hours.
For instructions on reconstitution of the medicinal product before administration, see section 6.6 and the package leaflet.
- Known hypersensitivity to the active substance or to any of the excipients.
- Known allergic reactions to mouse or hamster protein.
Hypersensitivity reactions
As with any intravenous protein product, allergic type hypersensitivity reactions are possible.
Patients should be made aware that the potential occurrence of chest tightness, dizziness, mild hypotension and nausea during infusion can constitute an early warning for hypersensitivity and anaphylactic reactions. Symptomatic treatment and therapy for hypersensitivity should be instituted as appropriate. If allergic or anaphylactic reactions occur, the injection/infusion should be stopped immediately and patient should contact their physician. In case of shock, the current medical standards for shock treatment should be observed.
Antibodies (inhibitors)
The formation of neutralising antibodies (inhibitors) to factor VIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Modified Bethesda Units (BU) per ml of plasma. The risk of developing inhibitors is correlated to the exposure to anti-haemophilic factor VIII and to genetic factors among others, this risk being highest within the first 20 exposure days. Rarely, inhibitors may develop after the first 100 exposure days.
Cases of recurrence of inhibitors (low titre) have been observed after switching from one recombinant factor VIII product to another in previously treated patients with more than 100 exposure days who have a history of inhibitor development.
Patients treated with recombinant coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests. (See also section 4.8)
Continuous infusion
In a clinical study about the use of continuous infusion in surgeries, heparin was used to prevent thrombophlebitis at the infusion site as with any other long term intravenous infusions.
Registration
In the interest of the patients, it is recommended that, whenever possible, every time that KOGENATE Bayer is administered to them, the name and the batch number of the product is registered.
Sodium content
This medicinal product contains less than 1 mmol sodium (23 mg) per vial, i.e. essentially “sodium free”.
No interactions of KOGENATE Bayer with other medicinal products are known.
Animal reproduction studies have not been conducted with KOGENATE Bayer.
Based on the rare occurrence of haemophilia A in women, experience regarding the use of KOGENATE Bayer during pregnancy and breast-feeding is not available. Therefore, KOGENATE Bayer should be used during pregnancy and breast-feeding only if clearly indicated.
There are no fertility data available.
KOGENATE Bayer has no influence on the ability to drive or to use machines.
The most commonly reported adverse drug reaction occurring is the formation of neutralising antibodies (prevalent in previously untreated or minimally treated patients).
The frequencies of adverse reactions reported with KOGENATE Bayer are summarized in the table below. Within each frequency group, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as common (
|
|
|
|
|
|
| |
|
|
| |
|
|
|
* see section below
Description of selected adverse reactions
The formation of neutralising antibodies to factor VIII (inhibitors) is a known complication in the management of individuals with haemophilia A. In studies with recombinant factor VIII preparations, development of inhibitors is predominantly observed in previously untreated haemophiliacs. Patients should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.
In clinical studies, KOGENATE Bayer has been used in the treatment of bleeding episodes in 37 previously untreated patients (PUPs) and 23 minimally treated pediatric patients (MTPs, defined as having equal to or less than 4 exposure days). Five out of 37 (14%) PUP and 4 out of 23 (17%) MTP patients treated with KOGENATE Bayer developed inhibitors: Overall, 9 out of 60 (15%) developed inhibitors, 6 out of 60 (10%) with a titre above 10 BU and 3 out of 60 (5%) with a titre below 10 BU. The median number of exposure days at the time of inhibitor detection in these patients was 9 days (range 3 - 18 days).
The median number of exposure days in the clinical studies was 114 (range: 4-478). Four of the five patients, who had not achieved 20 exposure days at the end of the study, ultimately achieved more than 20 exposure days in post-study follow-up and one of them developed a low titre inhibitor. The fifth patient was lost to follow-up.
In clinical studies with 73 previously treated patients (PTP, defined as having more than 100 exposure days), followed over four years, no de-novo inhibitors were observed.
In extensive post-registration studies with KOGENATE Bayer, involving more than 1000 patients the following was observed: Less than 0.2% PTP developed de-novo inhibitors. In a subset defined as having less than 20 exposure days at study entry, less than 11% developed de-novo inhibitors.
During studies, no patient developed clinically relevant antibody titres against the trace amounts of mouse protein and hamster protein present in the preparation. However, the possibility of allergic reactions to constituents, e.g. trace amounts of mouse and hamster protein in the preparation exists in certain predisposed patients (see sections 4.3 and 4.4).
No case of overdose with recombinant coagulation factor VIII has been reported.
Pharmacotherapeutic group: antihemorrhagics: blood coagulation factor VIII, ATC code B02BD02.
The factor VIII/von Willebrand factor (vWF) complex consists of two molecules (factor VIII and vWF) with different physiological functions. When infused into a haemophilic patient, factor VIII binds to vWF in the patient's circulation. Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X. Activated factor X converts prothrombin into thrombin. Thrombin then converts fibrinogen into fibrin and a clot can be formed. Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C and results in profuse bleeding into joints, muscles or internal organs, either spontaneously or as a result of accidental or surgical trauma. By replacement therapy the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.
Determination of activated partial thromboplastin time (aPTT) is a conventional in vitro assay method for biological activity of factor VIII. The aPTT is prolonged in all haemophiliacs. The degree and duration of aPTT normalisation observed after administration of KOGENATE Bayer is similar to that achieved with plasma-derived factor VIII.
The analysis of all recorded in vivo recoveries in previously treated patients demonstrated a mean rise of 2 % per IU/kg body weight for KOGENATE Bayer. This result is similar to the reported values for factor VIII derived from human plasma.
After administration of KOGENATE Bayer, peak factor VIII activity decreased by a two-phase exponential decay with a mean terminal half-life of about 15 hours. This is similar to that of plasma-derived factor VIII which has a mean terminal half-life of approx. 13 hours. Additional pharmacokinetic parameters for KOGENATE Bayer for bolus injection are: mean residence time [MRT (0-48)] of about 22 hours and clearance of about 160 ml/h. Mean baseline clearance for 14 adult patients undergoing major surgeries with continuous infusion are 188 ml/h corresponding to 3.0 ml/h/kg (range 1.6-4.6 ml/h/kg).
Even doses several fold higher than the recommended clinical dose (related to body weight) failed to demonstrate any acute or subacute toxic effects for KOGENATE Bayer in laboratory animals (mouse, rat, rabbit, and dog).
Specific studies with repeated administration such as reproduction toxicity, chronic toxicity, and carcinogenicity were not performed with octocog alfa due to the immune response to heterologous proteins in all non-human mammalian species.
No studies were performed on the mutagenic potential of KOGENATE Bayer, since no mutagenic potential could be detected in vitro or in vivo for the predecessor product of KOGENATE Bayer.
Powder
Glycine
Sodium chloride
Calcium chloride
Histidine
Polysorbate 80
Sucrose
Solvent
Water for injections
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.
Only the provided components (powder vial, pre-filled syringe containing solvent, vial adapter and venipuncture set) should be used for reconstitution and injection because treatment failure can occur as a consequence of human recombinant coagulation factor VIII adsorption to the internal surfaces of some infusion equipment.
30 months.
After reconstitution, the product should be used immediately.
However, during in vitro studies, the chemical and physical in-use stability has been demonstrated for 24 hours at 30°C in PVC bags for continuous infusion.
Do not refrigerate after reconstitution.
Store in a refrigerator (2°C – 8°C). Do not freeze. Keep the vial and the pre-filled syringe in the outer carton in order to protect from light.
The product when kept in its outer carton may be stored at ambient room temperature (up to 25°C) for a limited period of 12 months. In this case, the product expires at the end of this 12-month period; the new expiry date must be noted on the outer carton.
For storage conditions of the reconstituted medicinal product, see section 6.3.
Each package of KOGENATE Bayer contains:
• one vial with powder (10 ml clear glass type 1 vial with latex-free grey halogenobutyl rubber blend stopper and aluminium seal)
• one pre-filled syringe with 5.0 ml solvent (clear glass cylinder type 1 with latex-free grey bromobutyl rubber blend stopper)
• syringe plunger rod
• vial adapter
• one venipuncture set
• two sterile alcohol swabs for single use
• two dry swabs
• two plasters
Detailed instructions for preparation and administration are contained in the package leaflet provided with KOGENATE Bayer.
KOGENATE Bayer powder should only be reconstituted with the supplied solvent (5.0 ml water for injections) in the prefilled syringe and the vial adapter. Reconstitution should be performed in accordance with good practices rules, particularly with attention to asepsis. Gently rotate the vial until all powder is dissolved. After reconstitution the solution is clear. Do not use KOGENATE Bayer if you notice visible particulate matter or turbidity.
After reconstitution, the solution is drawn back into the syringe.
Use the provided venipuncture set for intravenous injection.
For continuous infusion, the product must be prepared under aseptic conditions.
For single use only. Any unused solution must be discarded.
Any unused product or waste material should be disposed of in accordance with local requirements.
Bayer Pharma AG
13342 Berlin
Germany
EU/1/00/143/011
Date of first authorisation: 04 August 2000
Date of latest renewal: 06 August 2010
1 July 2011
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Tramadol-Sandoz may be available in the countries listed below.
Tramadol hydrochloride (a derivative of Tramadol) is reported as an ingredient of Tramadol-Sandoz in the following countries:
International Drug Name Search
Riva-Dicyclomine may be available in the countries listed below.
Dicycloverine hydrochloride (a derivative of Dicycloverine) is reported as an ingredient of Riva-Dicyclomine in the following countries:
International Drug Name Search
Phenazopyridine hydrochloride (a derivative of Phenazopyridine) is reported as an ingredient of Azo-Natural in the following countries:
International Drug Name Search
Calblock may be available in the countries listed below.
Azelnidipine is reported as an ingredient of Calblock in the following countries:
International Drug Name Search
Glaucocare may be available in the countries listed below.
Aceclidine hydrochloride (a derivative of Aceclidine) is reported as an ingredient of Glaucocare in the following countries:
International Drug Name Search
Itraconazolo DOC may be available in the countries listed below.
Itraconazole is reported as an ingredient of Itraconazolo DOC in the following countries:
International Drug Name Search
Gardal may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Albendazole is reported as an ingredient of Gardal in the following countries:
Albendazole oxide (a derivative of Albendazole) is reported as an ingredient of Gardal in the following countries:
International Drug Name Search
Calcium-Sandoz D3 f/ - D3 ff may be available in the countries listed below.
Calcium mixture of several salts (a derivative of Calcium) is reported as an ingredient of Calcium-Sandoz D3 f/ - D3 ff in the following countries:
Colecalciferol is reported as an ingredient of Calcium-Sandoz D3 f/ - D3 ff in the following countries:
International Drug Name Search
Frotan may be available in the countries listed below.
Frovatriptan is reported as an ingredient of Frotan in the following countries:
International Drug Name Search
Fluoxetina Angenerico may be available in the countries listed below.
Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Fluoxetina Angenerico in the following countries:
International Drug Name Search
Larotin may be available in the countries listed below.
Loratadine is reported as an ingredient of Larotin in the following countries:
International Drug Name Search
Mono Tildiem may be available in the countries listed below.
Diltiazem is reported as an ingredient of Mono Tildiem in the following countries:
Diltiazem hydrochloride (a derivative of Diltiazem) is reported as an ingredient of Mono Tildiem in the following countries:
International Drug Name Search
alozur may be available in the countries listed below.
Amlodipine is reported as an ingredient of alozur in the following countries:
International Drug Name Search
Aspecardum may be available in the countries listed below.
Acetylsalicylic Acid is reported as an ingredient of Aspecardum in the following countries:
International Drug Name Search
Poncoflox may be available in the countries listed below.
Ciprofloxacin is reported as an ingredient of Poncoflox in the following countries:
International Drug Name Search
Brimontal may be available in the countries listed below.
Brimonidine tartrate (a derivative of Brimonidine) is reported as an ingredient of Brimontal in the following countries:
International Drug Name Search
Ranibos may be available in the countries listed below.
Ranitidine is reported as an ingredient of Ranibos in the following countries:
International Drug Name Search
Induzepam may be available in the countries listed below.
Clonazepam is reported as an ingredient of Induzepam in the following countries:
International Drug Name Search
Isosol may be available in the countries listed below.
Povidone-Iodine is reported as an ingredient of Isosol in the following countries:
International Drug Name Search
Rynex may be available in the countries listed below.
Oxymetazoline hydrochloride (a derivative of Oxymetazoline) is reported as an ingredient of Rynex in the following countries:
International Drug Name Search
Movithiol may be available in the countries listed below.
Betamethasone 17α-valerate (a derivative of Betamethasone) is reported as an ingredient of Movithiol in the following countries:
International Drug Name Search
Amoxivan may be available in the countries listed below.
Amoxicillin is reported as an ingredient of Amoxivan in the following countries:
Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Amoxivan in the following countries:
International Drug Name Search
Alprazolam Bluepharma may be available in the countries listed below.
Alprazolam is reported as an ingredient of Alprazolam Bluepharma in the following countries:
International Drug Name Search
Lamotren may be available in the countries listed below.
Lamotrigine is reported as an ingredient of Lamotren in the following countries:
International Drug Name Search
Matil may be available in the countries listed below.
Amisulpride is reported as an ingredient of Matil in the following countries:
International Drug Name Search
Fentanyl Actavis may be available in the countries listed below.
Fentanyl is reported as an ingredient of Fentanyl Actavis in the following countries:
International Drug Name Search
Itrop may be available in the countries listed below.
Ipratropium Bromide monohydrate (a derivative of Ipratropium Bromide) is reported as an ingredient of Itrop in the following countries:
International Drug Name Search
Bestasone may be available in the countries listed below.
Fluocinonide is reported as an ingredient of Bestasone in the following countries:
International Drug Name Search
Loxonin may be available in the countries listed below.
Loxoprofen sodium salt (a derivative of Loxoprofen) is reported as an ingredient of Loxonin in the following countries:
International Drug Name Search
Gonavet may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Gonadorelin acetate (a derivative of Gonadorelin) is reported as an ingredient of Gonavet in the following countries:
International Drug Name Search
Pentamidina Combino Pharm may be available in the countries listed below.
Pentamidine isetionate (a derivative of Pentamidine) is reported as an ingredient of Pentamidina Combino Pharm in the following countries:
International Drug Name Search
Parkotil may be available in the countries listed below.
Pergolide mesilate (a derivative of Pergolide) is reported as an ingredient of Parkotil in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
In the US, Pilocarpine (pilocarpine systemic) is a member of the drug class cholinergic agonists and is used to treat Xerostomia.
US matches:
UK matches:
BAN
N07AX01,S01EB01
0000092-13-7
C11-H16-N2-O2
208
Parasympathomimetic agent, direct acting
2(3H)-Furanone, 3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-, (3S-cis)-
International Drug Name Search
Glossary
| BAN | British Approved Name |
| BANM | British Approved Name (Modified) |
| DCF | Dénomination Commune Française |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| SPC | Summary of Product Characteristics (UK) |
Midocin may be available in the countries listed below.
Clindamycin is reported as an ingredient of Midocin in the following countries:
International Drug Name Search
Apo-Ferrous Sulfate may be available in the countries listed below.
Ferrous Sulfate is reported as an ingredient of Apo-Ferrous Sulfate in the following countries:
International Drug Name Search
Indo-Bros may be available in the countries listed below.
Tenoxicam is reported as an ingredient of Indo-Bros in the following countries:
International Drug Name Search
In the US, Alaway (ketotifen ophthalmic) is a member of the drug class ophthalmic antihistamines and decongestants and is used to treat Conjunctivitis, Allergic.
US matches:
Ketotifen is reported as an ingredient of Alaway in the following countries:
Ketotifen fumarate (a derivative of Ketotifen) is reported as an ingredient of Alaway in the following countries:
International Drug Name Search
Trophicrème may be available in the countries listed below.
Estriol is reported as an ingredient of Trophicrème in the following countries:
International Drug Name Search
Masaquin may be available in the countries listed below.
Chloroquine phosphate (a derivative of Chloroquine) is reported as an ingredient of Masaquin in the following countries:
International Drug Name Search
Famogast D may be available in the countries listed below.
Famotidine is reported as an ingredient of Famogast D in the following countries:
International Drug Name Search
Ferro Duretter may be available in the countries listed below.
Ferrous Sulfate is reported as an ingredient of Ferro Duretter in the following countries:
International Drug Name Search
Ferrolent may be available in the countries listed below.
Ferrous Sulfate is reported as an ingredient of Ferrolent in the following countries:
International Drug Name Search
Cérubidine may be available in the countries listed below.
Daunorubicin hydrochloride (a derivative of Daunorubicin) is reported as an ingredient of Cérubidine in the following countries:
International Drug Name Search
Carboplatin Sandoz may be available in the countries listed below.
Carboplatin is reported as an ingredient of Carboplatin Sandoz in the following countries:
International Drug Name Search
Perfusalgan may be available in the countries listed below.
Paracetamol is reported as an ingredient of Perfusalgan in the following countries:
International Drug Name Search
Butasan may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Phenylbutazone is reported as an ingredient of Butasan in the following countries:
International Drug Name Search
Priadel may be available in the countries listed below.
UK matches:
Lithium carbonate (a derivative of Lithium) is reported as an ingredient of Priadel in the following countries:
Lithium citrate (a derivative of Lithium) is reported as an ingredient of Priadel in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Keramo may be available in the countries listed below.
Famotidine is reported as an ingredient of Keramo in the following countries:
International Drug Name Search
Pantoprazol acis may be available in the countries listed below.
Pantoprazole sodium (a derivative of Pantoprazole) is reported as an ingredient of Pantoprazol acis in the following countries:
International Drug Name Search
Propanline may be available in the countries listed below.
Propantheline Bromide is reported as an ingredient of Propanline in the following countries:
International Drug Name Search
Perfenazine CF may be available in the countries listed below.
Perphenazine is reported as an ingredient of Perfenazine CF in the following countries:
International Drug Name Search
Emflam may be available in the countries listed below.
Ibuprofen is reported as an ingredient of Emflam in the following countries:
International Drug Name Search
Adco-Ketotifen may be available in the countries listed below.
Ketotifen fumarate (a derivative of Ketotifen) is reported as an ingredient of Adco-Ketotifen in the following countries:
International Drug Name Search
Ranitidine RPG may be available in the countries listed below.
Ranitidine hydrochloride (a derivative of Ranitidine) is reported as an ingredient of Ranitidine RPG in the following countries:
International Drug Name Search
Triatec-30 may be available in the countries listed below.
Codeine phosphate hemihydrate (a derivative of Codeine) is reported as an ingredient of Triatec-30 in the following countries:
Paracetamol is reported as an ingredient of Triatec-30 in the following countries:
International Drug Name Search
Ceff may be available in the countries listed below.
Cefalexin is reported as an ingredient of Ceff in the following countries:
International Drug Name Search
Liquemine may be available in the countries listed below.
Heparin is reported as an ingredient of Liquemine in the following countries:
International Drug Name Search
Triméthadione may be available in the countries listed below.
Triméthadione (DCF) is known as Trimethadione in the US.
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
Acido Alendronico Ossys may be available in the countries listed below.
Alendronic Acid is reported as an ingredient of Acido Alendronico Ossys in the following countries:
International Drug Name Search
Cinal may be available in the countries listed below.
Ascorbic Acid is reported as an ingredient of Cinal in the following countries:
Calcium Pantothenate is reported as an ingredient of Cinal in the following countries:
International Drug Name Search
Indapamide EG may be available in the countries listed below.
Indapamide is reported as an ingredient of Indapamide EG in the following countries:
International Drug Name Search
Loratadina Edigen may be available in the countries listed below.
Loratadine is reported as an ingredient of Loratadina Edigen in the following countries:
International Drug Name Search